Exploiting and defining the immune regulatory activities of BET bromodomain inhibitors

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1151409

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Immune-based agents such as “checkpoint inhibitors” have the ability to re-awaken our own immune systems and activate previously dormant anti-tumour responses. We have discovered that small molecule inhibitors of gene regulatory proteins called bromodomain proteins act synergistically with checkpoint inhibitors in mouse cancer models. I will define the molecular and biological events underpinning this novel combination approach and assess the effects of the combination across different tumours.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2021

Funding Scheme: Postgraduate Scholarships

Funding Amount: $128,224.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Haematological Tumours

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

apoptosis | cancer biology | epigenetics | immune modulation | therapeutic antibodies

Related Links